NCT00725608View on ClinicalTrials.gov

Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)

CompletedOBSERVATIONAL

Enrollment

339

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Opioid-Related DisordersOpiate DependenceDrug Abuse

Interventions

DRUG

buprenorphine/naloxone

2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months

Trial Locations (1)

1070

(Multiple sites in Austria) => Coordinating CRO: H&P GmbH, Vienna